CD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss.

Hdl Handle:
http://hdl.handle.net/10147/208875
Title:
CD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss.
Authors:
Drummond, Frances J; Mackrill, John J; O'sullivan, Kathleen; Daly, Mary; Shanahan, Fergus; Molloy, Michael G
Affiliation:
Department of Rheumatology and Medicine, Clinical Sciences Building, Cork, University Hospital, National University of Ireland, Cork, Ireland., f.drummond@ncri.ie
Citation:
J Bone Miner Metab. 2006;24(1):28-35.
Journal:
Journal of bone and mineral metabolism
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/208875
DOI:
10.1007/s00774-005-0642-3
PubMed ID:
16369895
Abstract:
One goal of osteoporosis research is to identify the genes and environmental factors that contribute to low bone mineral density (BMD) and fracture. Linkage analyses have identified quantitative trait loci (QTLs), however, the genes contributing to low BMD are largely unknown. We examined the potential association of an intronic polymorphism in CD38 with BMD and postmenopausal bone loss. CD38 resides in 4p15, where a QTL for BMD has been described. CD38-/- mice display an osteoporotic phenotype at 3 months, with normalization of BMD by 5 months. The CD38 polymorphism was identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis in 457 postmenopausal and 173 premenopausal Caucasian women whose spine and hip BMD was measured by dual energy X-ray absorptiometry (DXA). Influence of the CD38 polymorphism on bone loss was analyzed in 273 postmenopausal women over a follow-up of 2.94 +/- 1.50 years. The CD38-PvuII polymorphism was significantly associated with premenopausal and postmenopausal (P = 0.001) lumbar spine BMD. Women homozygous for the G allele had >14% lower spinal BMD than women with GC/CC genotypes. An allele dose effect was observed at the spine in premenopausal (P = 0.002) and postmenopausal (P < 0.001) cohorts. The CD38-PvuII polymorphism was significantly associated with femoral neck BMD in pre- and postmenopausal women (P = 0.002 and P = 0.011, respectively). However, significance was lost following adjustment of hip BMD for covariates in the postmenopausal cohort (P = 0.081). The CD38-PvuII polymorphism was weakly associated with bone loss at the spine (P = 0.024), in postmenopausal women not taking hormone replacement therapy. We suggest that the CD38-PvuII polymorphism may influence the attainment and maintenance of peak BMD and postmenopausal bone loss.
Language:
eng
MeSH:
Adult; Analysis of Variance; Antigens, CD38/*genetics; Bone Density/*genetics; Case-Control Studies; Female; Follow-Up Studies; Genotype; Humans; Membrane Glycoproteins/*genetics; Middle Aged; Osteoporosis, Postmenopausal/*genetics; *Polymorphism, Genetic; Postmenopause; Premenopause; Receptors, Estrogen/*genetics
ISSN:
0914-8779 (Print); 0914-8779 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorDrummond, Frances Jen_GB
dc.contributor.authorMackrill, John Jen_GB
dc.contributor.authorO'sullivan, Kathleenen_GB
dc.contributor.authorDaly, Maryen_GB
dc.contributor.authorShanahan, Fergusen_GB
dc.contributor.authorMolloy, Michael Gen_GB
dc.date.accessioned2012-02-03T15:06:10Z-
dc.date.available2012-02-03T15:06:10Z-
dc.date.issued2012-02-03T15:06:10Z-
dc.identifier.citationJ Bone Miner Metab. 2006;24(1):28-35.en_GB
dc.identifier.issn0914-8779 (Print)en_GB
dc.identifier.issn0914-8779 (Linking)en_GB
dc.identifier.pmid16369895en_GB
dc.identifier.doi10.1007/s00774-005-0642-3en_GB
dc.identifier.urihttp://hdl.handle.net/10147/208875-
dc.description.abstractOne goal of osteoporosis research is to identify the genes and environmental factors that contribute to low bone mineral density (BMD) and fracture. Linkage analyses have identified quantitative trait loci (QTLs), however, the genes contributing to low BMD are largely unknown. We examined the potential association of an intronic polymorphism in CD38 with BMD and postmenopausal bone loss. CD38 resides in 4p15, where a QTL for BMD has been described. CD38-/- mice display an osteoporotic phenotype at 3 months, with normalization of BMD by 5 months. The CD38 polymorphism was identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis in 457 postmenopausal and 173 premenopausal Caucasian women whose spine and hip BMD was measured by dual energy X-ray absorptiometry (DXA). Influence of the CD38 polymorphism on bone loss was analyzed in 273 postmenopausal women over a follow-up of 2.94 +/- 1.50 years. The CD38-PvuII polymorphism was significantly associated with premenopausal and postmenopausal (P = 0.001) lumbar spine BMD. Women homozygous for the G allele had >14% lower spinal BMD than women with GC/CC genotypes. An allele dose effect was observed at the spine in premenopausal (P = 0.002) and postmenopausal (P < 0.001) cohorts. The CD38-PvuII polymorphism was significantly associated with femoral neck BMD in pre- and postmenopausal women (P = 0.002 and P = 0.011, respectively). However, significance was lost following adjustment of hip BMD for covariates in the postmenopausal cohort (P = 0.081). The CD38-PvuII polymorphism was weakly associated with bone loss at the spine (P = 0.024), in postmenopausal women not taking hormone replacement therapy. We suggest that the CD38-PvuII polymorphism may influence the attainment and maintenance of peak BMD and postmenopausal bone loss.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAnalysis of Varianceen_GB
dc.subject.meshAntigens, CD38/*geneticsen_GB
dc.subject.meshBone Density/*geneticsen_GB
dc.subject.meshCase-Control Studiesen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshFollow-Up Studiesen_GB
dc.subject.meshGenotypeen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMembrane Glycoproteins/*geneticsen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshOsteoporosis, Postmenopausal/*geneticsen_GB
dc.subject.mesh*Polymorphism, Geneticen_GB
dc.subject.meshPostmenopauseen_GB
dc.subject.meshPremenopauseen_GB
dc.subject.meshReceptors, Estrogen/*geneticsen_GB
dc.titleCD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss.en_GB
dc.contributor.departmentDepartment of Rheumatology and Medicine, Clinical Sciences Building, Cork, University Hospital, National University of Ireland, Cork, Ireland., f.drummond@ncri.ieen_GB
dc.identifier.journalJournal of bone and mineral metabolismen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.